Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | AZD2516 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD2516 | Drug | Fractionated single oral dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Positron emission tomography to determine if AZD2516 can displace the radioligand [11C]AZ12713580 and describe relationship between AZD2516 exposure and mGluR5 receptor occupancy | 1 Month: Baseline and 3 PET examinations |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of AZD2516 by adverse events, vitals signs, ECG, body temperature and laboratory variables | Assessed at each visit from baseline to follow-up visit | |
| To investigate the Pharmacokinetics of AZD2516 | 1 Month: 3 doses AZD2516 and 16 planned PK samples after each dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ingemar Bylesjo, MD, PhD | AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden | Principal Investigator |
| Michael O'Malley | AstraZeneca R&D, Södertälje, Sweden | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Stockholm | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided